| |
Tofacitinib (n = 161)
|
Baricitinib (n = 81)
|
P value
|
|---|
|
All Events, n (%)
|
32 (19.9)
|
17 (21.0)
|
0.866
|
|
Infection
|
20 (12.4)
|
11 (13.6)
|
0.840
|
|
Herpes zoster
|
9 (5.6)
|
4 (4.9)
| |
|
Pneumonia
|
6 (3.7)
|
1 (1.2)
| |
|
Upper respiratory infection
|
4 (2.5)
|
3 (3.7)
| |
|
Callus infection
| |
1 (1.2)
| |
|
Cytomegalovirus infection
| |
1 (1.2)
| |
|
Fungus infection
|
1 (0.6)
| | |
|
Sepsis
| |
1 (1.2)
| |
|
Gastrointestinal disorder
|
6 (3.7)
|
2 (2.5)
|
0.720
|
|
Gastric ulcer
| |
1 (1.2)
| |
|
Nausea
|
4 (2.5)
|
1 (1.2)
| |
|
Diarrhea
|
2 (1.2)
| | |
|
Neoplasm
|
3 (1.9)
|
1 (1.2)
|
> 0.999
|
|
Breast cancer
| |
1 (1.2)
| |
|
Colon cancer
|
1 (0.6)
| | |
|
Skin cancer
|
1 (0.6)
| | |
|
Lung cancer
|
1 (0.6)
| | |
|
Others
|
3 (1.9)
|
3 (3.7)
|
0.405
|
|
Hair loss
|
1 (0.6)
| | |
|
Vertigo
|
1 (0.6)
|
1 (1.2)
| |
|
Headache
| |
1 (1.2)
| |
|
Interstitial pneumonia
|
1 (0.6)
| | |
|
Elevation of creatine kinase
| |
1 (1.2)
| |
